July 26 (Reuters) - Drugmaker Bristol Myers Squibb

posted better-than-expected second-quarter results,

driven by growth from new products like anemia treatment

Reblozyl and heart drug Camzyos as well as from its top-seller,

blood thinner Eliquis.

The company also raised its earnings forecast for the full

year.

"You're really seeing the transformation of our business to

the new growth portfolio," Chief Financial Officer David Elkins

said in an interview.

Last year, the company said it needed more time to hit its

growth targets for its new drugs, pushing back by a year the

time frame for its new-product portfolio to hit $10 billion in

revenue.

Sales from its so-called growth portfolio, which includes

new products as well as some established brands like cancer

immunotherapy Opdivo, grew 18% year-over-year.

Total revenue in the quarter was $12.2 billion, up about 9%

from $11.2 billion last year. Analysts, on average, had expected

revenue of $11.5 billion, according to LSEG data.

Bristol Myers earned $1.68 billion, or 83 cents a share, in

the quarter, down from $2.07 billion, or 99 cents a share last

year. Excluding one-time items, the drugmaker said it earned

$2.07 a share in the quarter, compared with analyst estimates of

$1.63 a share.

The company reported sales of $3.4 billion, up 7% from last

year, for current top-seller Eliquis in the quarter. That was in

line with analyst expectations.

The drug is expected to have revenue somewhat curtailed when

the U.S. Medicare health plan for people over age 65 institutes

negotiated drug prices starting in 2026.

Bristol Myers executives said they had received a price for

the drug from the U.S. regulators, but declined to comment

further on the process until the price is made public by Sept.

1.

The company said sales of Opdivo rose 11% to $2.4 billion in

the second quarter. Sales of anemia drug Reblozyl rose 82% from

last year to $425 million and Camzyos sales more than tripled to

$139 million.

Bristol Myers said it now expects full-year earnings of 60

to 90 cents a share, up from its previous estimate of 40 to 70

cents a share. Analysts had forecast full year earnings of 51

cents a share.

The company's shares closed at $45.27 on Thursday, down

around 14% so far this year.